Past President of the American Burn Association Dr. David Ahrenholz Provides Video Interview on Potential of ESS for Treatment of Severe Burns
October 14, 2015 10:30 ET
|
Amarantus BioScience Holdings, Inc.
SAN FRANCISCO and GENEVA, Oct. 14, 2015 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in...
Amarantus Reports Preliminary 13-Year Longitudinal Follow-Up Human Patient Data for Engineered Skin Substitute Treatment of Congenital Giant Hairy Nevus
October 08, 2015 08:33 ET
|
Amarantus BioScience Holdings, Inc.
- Single ESS Treatment Provided Successful Skin Replacement on Infant Patient, Supporting Natural Skin Growth That Required no Additional Grafts or Reconstructive Surgery - Data Provides...
Amarantus Announces Publication of Study on Targeted Delivery of MANF to Brain Areas Associated With Parkinson's Disease
October 06, 2015 08:30 ET
|
Amarantus BioScience Holdings, Inc.
- Renishaw plc’s convection-enhanced delivery device results in accurate targeting and distribution of MANF to Parkinson’s disease-associated brain areas - - Study confirms the potential of...
Amarantus to Present at the 2015 Aegis Growth Conference
October 05, 2015 10:47 ET
|
Amarantus BioScience Holdings, Inc.
SAN FRANCISCO and GENEVA, Oct. 05, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in...
Amarantus to Focus Near-Term Development Efforts on Engineered Skin Substitute for Indications in Rare Pediatric Diseases
October 01, 2015 09:25 ET
|
Amarantus BioScience Holdings, Inc.
Company is Currently Evaluating Human Clinical Data From Previous Studies Supporting
Clinical Development Program Expansion Beyond Treatment of Adult Burns Into Pediatric Burns
Published Data...
Amarantus Closes $5.5 Million Capital Infusion Through the Issuance of a Combination of Preferred Stock and Secured Debt Convertible
October 01, 2015 07:32 ET
|
Amarantus BioScience Holdings, Inc.
SAN FRANCISCO and GENEVA, Oct. 1, 2015 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates for orphan...
Amarantus Receives Orphan Drug Designation From the U.S. Food and Drug Administration for MANF for the Treatment of Retinal Artery Occlusion
September 14, 2015 10:30 ET
|
Amarantus BioScience Holdings, Inc.
SAN FRANCISCO and GENEVA, Sept. 14, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in...
Amarantus Announces Results of Annual Meeting
September 03, 2015 07:05 ET
|
Amarantus BioScience Holdings, Inc.
SAN FRANCISCO and GENEVA, Sept. 3, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan...
Amarantus Moves Annual Meeting Date Forward to September 2, 2015
August 26, 2015 12:30 ET
|
Amarantus BioScience Holdings, Inc.
SAN FRANCISCO and GENEVA, Aug. 26, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan...
Amarantus Announces Issuance of United States Patent Covering Proprietary Compositions of Matter and Methods of Use for Product Candidate MANF
August 20, 2015 08:35 ET
|
Amarantus BioScience Holdings, Inc.
SAN FRANCISCO and GENEVA, Aug. 20, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan...